361 related articles for article (PubMed ID: 17824579)
21. Managing myelodysplastic syndromes.
Kurtin S
Oncology (Williston Park); 2007 Feb; 21(2 Suppl Nurse Ed):45-6. PubMed ID: 17474364
[No Abstract] [Full Text] [Related]
22. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
23. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Tannemaat MR; Vries EP; Molendijk WJ; Haan J
Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
[No Abstract] [Full Text] [Related]
24. Concurrent radiation therapy and lenalidomide in myeloma patient.
Marchand V; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Apr; 87(1):152-3. PubMed ID: 18077032
[No Abstract] [Full Text] [Related]
25. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
26. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
Miller KC; Musial L; Whitworth A; Chanan-Khan A
Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
[TBL] [Abstract][Full Text] [Related]
27. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
28. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
van de Donk NW; Wittebol S; Minnema MC; Lokhorst HM
Br J Haematol; 2010 Jan; 148(2):335-7. PubMed ID: 20085583
[No Abstract] [Full Text] [Related]
29. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Jena RK; Swain TR; Kansurkar SS; Swain M
Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
[TBL] [Abstract][Full Text] [Related]
30. Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Coutinho R; Costa D; Carrió A; Muñoz C; Vidal A; Belkaid M; Campo E; Nomdedeu B
Ann Hematol; 2010 Oct; 89(10):1069-70. PubMed ID: 20232065
[No Abstract] [Full Text] [Related]
31. Immunomodulatory drugs.
Crane E; List A
Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
[TBL] [Abstract][Full Text] [Related]
32. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
Kurtin S; Sokol L
Cancer Control; 2006 Dec; 13 Suppl():26-31. PubMed ID: 17242664
[TBL] [Abstract][Full Text] [Related]
33. The evolving role of lenalidomide in the treatment of hematologic malignancies.
Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2007 Mar; 8(4):497-509. PubMed ID: 17309344
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous adverse reactions to lenalidomide.
Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide in multiple myeloma: Current status and future potential.
Quach H; Kalff A; Spencer A
Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
Pretz J; Medeiros BC
Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102
[No Abstract] [Full Text] [Related]
37. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
38. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Eclache V; Da Rocha A; Le Roux G; Fenaux P
Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
[TBL] [Abstract][Full Text] [Related]
39. Management of the adverse effects of lenalidomide in multiple myeloma.
González Rodríguez AP
Adv Ther; 2011 Mar; 28 Suppl 1():1-10. PubMed ID: 21431626
[TBL] [Abstract][Full Text] [Related]
40. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
